Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progress toward Gene Therapy for Duchenne Muscular Dystrophy.

Joel R Chamberlain1, Jeffrey S Chamberlain2

  • 1Department of Medicine, University of Washington, Seattle, WA 98195, USA; Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center, University of Washington, Seattle, WA 98195, USA.

Molecular Therapy : the Journal of the American Society of Gene Therapy
|April 19, 2017
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantitative MRI Assessment of Myotoxin-Induced Skeletal Muscle Damage of mdx Mice.

Muscle & nerve·2026
Same author

Dystrophins DP71 and DP427 determine cell viability during proliferation and myofibre differentiation.

Cell death & disease·2026
Same author

Genetic strategies for therapy of Duchenne muscular dystrophy.

Molecular therapy. Nucleic acids·2025
Same author

Proteomics-based evaluation of AAV dystrophin gene therapy outcomes in mdx skeletal muscle.

JCI insight·2025
Same author

The future of gene therapy: Safer vectors, sharper focus: High-profile failures demand deep root cause analysis - but the transformative potential of AAV remains within reach if the field is willing to learn and evolve.

Molecular therapy : the journal of the American Society of Gene Therapy·2025
Same author

Bidirectional role of Costameres in the pathophysiology of mdx skeletal muscles.

Human molecular genetics·2025

Gene therapy for Duchenne muscular dystrophy (DMD) has progressed significantly over 30 years. This review highlights advancements toward successful human clinical trials for this genetic disease.

Area of Science:

  • * Genetics and Molecular Biology
  • * Biomedical Engineering
  • * Neuromuscular Disorders

Background:

  • * Duchenne muscular dystrophy (DMD) is a common, severe genetic disorder affecting muscle tissue.
  • * The DMD gene, encoding dystrophin, was the first human disease gene cloned without prior protein identification.
  • * Gene replacement therapy is a primary therapeutic strategy for DMD.

Observation:

  • * Significant scientific and patient advocacy efforts have addressed DMD gene therapy challenges.
  • * The large size of the DMD gene and extensive muscle tissue present major hurdles.
  • * Progress has been documented in scientific literature, particularly in Molecular Therapy.

Findings:

  • * Decades of research have overcome substantial obstacles in DMD gene therapy development.
Keywords:
AAVdystrophingene therapymdx micemicrodystrophinmuscular dystrophy

Related Experiment Videos

  • * Advancements pave the way for imminent human clinical trials.
  • * The review synthesizes progress and future prospects for DMD gene therapy.

    • Implications:

    • * Successful gene therapy could offer a transformative treatment for DMD patients.
    • * This research highlights the potential of gene replacement for genetic diseases.
    • * Continued collaboration is crucial for translating research into clinical success.